PI3K and mTOR signaling pathways in cancer: new data on targeted therapies (Q34164683)

31 July 2017

title

PI3K and mTOR signaling pathways in cancer: new data on targeted therapies (English)

1 reference

31 July 2017

Nicolas Chapuis

3

0 references

Jerome Tamburini

object named as

Jerome Tamburini

2

0 references

Didier Bouscary

object named as

Didier Bouscary

6

0 references

author name string

Lise Willems

1

1 reference

31 July 2017

Catherine Lacombe

4

1 reference

31 July 2017

Patrick Mayeux

5

1 reference

31 July 2017

language of work or name

1 reference

1 April 2012

1 reference

31 July 2017

published in

Current Oncology Reports

1 reference

31 July 2017

volume

14

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

129-138

1 reference

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

A critical role for Lyn in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Syk-dependent mTOR activation in follicular lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Activation of mTORC2 by Association with the Ribosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

mTOR signaling and drug development in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Predicted mechanisms of resistance to mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

New phosphatidylinositol 3-kinase inhibitors for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

mTORC2 protein complex-mediated Akt (Protein Kinase B) Serine 473 Phosphorylation is not required for Akt1 activity in human platelets [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

Akt and autophagy cooperate to promote survival of drug-resistant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-012-0227-Y

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

21 January 2018

1 reference

12 December 2020

Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo

1 reference

12 December 2020

The biological and therapeutic relevance of mRNA translation in cancer

1 reference

12 December 2020

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

12 December 2020

mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells

1 reference

12 December 2020

Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1

1 reference

12 December 2020

Defining the role of TORC1/2 in multiple myeloma

1 reference

12 December 2020

10.1007/S11912-012-0227-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1036198181

0 references

1 reference